论文部分内容阅读
目的探讨子宫内膜样腺癌及其癌前病变组织中PTEN、CyclinD1蛋白的表达及其临床意义。方法采用免疫组化SP法检测正常子宫内膜、内膜增生、非典型增生和子宫内膜样腺癌组织中PTEN和CyclinD1蛋白。结果非典型性增生和子宫内膜样腺癌组中PTEN和CyclinD1蛋白阳性表达率分别为55．0%、50．0%,40．0%和62．0%,两组中PTEN阳性表达均显著低于正常子宫内膜和子宫内膜增生组(P＜0．001),而CyclinD1则显著增高(P＜0．002),且两者在非典型性增生和子宫内膜样腺癌组中的表达均呈显著负相关(r=-0．7035、P＜0．05,r=-0．3493、P＜0．02)。癌组中PTEN阳性表达缺失与组织学分级(P＜0．02)、肌层浸润深度或伴有转移(P＜0．03)及临床分期有关(P＜0．03)。CyclinD1的阳性表达与肌层浸润(P＜0．005)和临床分期有关(P＜0．05)。癌组中肿瘤的复发分别与PTEN的低表达和CycHnD1的高表达有关(P＜0．05,P＜0．02)。结论PTEN表达缺失和CycfinD1的过度表达与子宫内膜样腺癌的发生、发展和肿瘤的复发密切相关,二者的联合检测可作为子宫内膜样癌的早期诊断、评价肿瘤生物学行为和预后、指导临床治疗的生物学指标。
Objective To investigate the expression of PTEN and CyclinD1 in endometrial adenocarcinoma and its precancerous lesions and its clinical significance. Methods The expressions of PTEN and CyclinD1 proteins in normal endometrium, endometrial hyperplasia, atypical hyperplasia and endometrioid adenocarcinoma were detected by immunohistochemical SP method. Results The positive rates of PTEN and CyclinD1 in atypical hyperplasia and endometrioid adenocarcinoma were 55.0%, 50.0%, 40.0% and 62.0%, respectively (P <0.001), and CyclinD1 was significantly higher (P <0.002), and both in atypical hyperplasia and endometrial adenocarcinoma group (R = -0.7035, P <0.05, r = -0.3493, P <0.02). The positive expression of PTEN in cancer group was correlated with histological grade (P <0.02), depth of myometrial invasion (P <0.03) and clinical stage (P <0.03). The positive expression of CyclinD1 was correlated with myometrial invasion (P <0.005) and clinical stage (P <0.05). The recurrence of tumor in cancer group was correlated with the low expression of PTEN and the high expression of CycHnD1 (P <0.05, P <0.02). Conclusions The loss of PTEN expression and the overexpression of CycfinD1 are closely related to the occurrence and development of endometrial adenocarcinoma and the recurrence of tumor. The combined detection of PTEN expression and endometrioid carcinoma can be used as an early diagnosis of endometrial carcinoma to evaluate the biological behavior and prognosis of endometrial carcinoma , To guide the clinical treatment of biological indicators.